Cellular, Histologic, and Molecular Changes Associated With Endometriosis and Ovarian Cancer

Journal of Minimally Invasive Gynecology

Volumn 21, Issue 1, 2014, Pages 55-63

  Siufi Neto, João ^a   Kho, Rosanne M ^a   dos Santos Siufi, Daniela Freitas ^a   Baracat, Edmund Chada ^c   Anderson, Karen S ^b   Abrão, Maurício Simões ^c  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Endometriosis; MicroRNA; Molecular alterations; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; HEPATOCYTE NUCLEAR FACTOR; K RAS PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

DISEASE ASSOCIATION; ENDOMETRIOSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; MOLECULAR DIAGNOSIS; OVARY CANCER; PATHOGENESIS; REVIEW;

ENDOMETRIOSIS; MICRORNA; MOLECULAR ALTERATIONS; OVARIAN CANCER;

CARCINOMA; ENDOMETRIOSIS; FEMALE; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 84891145065     PISSN: 15534650     EISSN: 15534669     Source Type: Journal    
DOI: 10.1016/j.jmig.2013.07.021     Document Type: Review

References (107)

1. Tariverdian N., Theoharides T.C., Siedentopf F., et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol 2007, 29:193-210.
2. Hudelist G., Keckstein J., Wright J.T. The migrating adenomyoma: past views on the etiology of adenomyosis and endometriosis. Fertil Steril 2009, 92:1536-1543.
3. Strathy J.H., Molgaard C.A., Coulam C.B., Melton L.J. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982, 38:667-672.
4. Giudice L.C. Clinical Practice. Endometriosis [Review]. N Engl J Med 2010, 362:2389-2398.
5. Abrao M.S., Sagae U.E., Gonzales M., Podgaec S., Dias J.A. Treatment of rectosigmoid endometriosis by laparoscopically assisted vaginal rectosigmoidectomy. Int J Gynaecol Obstet 2005, 91:27-31.
6. Kennedy S., Bergqvist A., Chapron C., et al. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005, 20:2698-2704.
7. Ajossa S., Mais V., Guerriero S., et al. The prevalence of endometriosis in premenopausal women undergoing gynecological surgery. Clin Exp Obstet Gynecol 1994, 21:195-197.
8. Vinatier D., Orazi G., Cosson M., Dufour P. Theories of endometriosis [Review]. Eur J Obstet Gynecol Reprod Biol 2001, 96:21-34.
9. Gazvani R., Templeton A. New considerations for the pathogenesis of endometriosis. Int J Gynaecol Obstet 2002, 76:117-126.
10. Munksgaard P.S., Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012, 124:164-169.
11. Borghese B., Mondon F., Noël J.C., et al. Gene expression profile for ectopic versus eutopic endometrium provides new insights into endometriosis oncogenic potential. Mol Endocrinol 2008, 22:2557-2562.
12. Thomas E.J., Campbell I.G. Evidence that endometriosis behaves in a malignant manner. Gynecol Obstet Invest 2000, 50(Suppl 1):2-10.
13. Brinton L.A., Gridley G., Persson I., Baron J., Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997, 176:572-579.
14. Brinton L.A., Lamb E.J., Moghissi K.S., et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004, 82:405-414.
15. Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. JOvarian Res 2010, 3:2.
16. Vlahos N.F., Kalampokas T., Fotiou S. Endometriosis and ovarian cancer: a review. Gynecol Endocrinol 2010, 26:213-219.
17. Somigliana E., Vigano P., Parazzini F. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006, 101:331-341.
18. Ogawa S., Kaku T., Amada S., et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000, 77:298-304.
19. Czernobilsky B., Morris W.J. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979, 53:318-323.
20. Prefumo F., Todeschini F., Fulcheri E., et al. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 2002, 84:280-284.
21. Sayasneh A., Tsivos D., Crawford R. Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol 2011, 2011:140310.
22. Wei J.J., William J., Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol 2011, 30:553-568.
23. Pearce C.L., Templeman C., Rossing M.A., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012, 13:385-394. Ovarian Cancer Association Consortium.
24. Kurman R.J., Shih I.M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
25. Bulun S.E. Endometriosis [Review]. N Engl J Med 2009, 360:268-279.
26. Olovsson M. Immunological aspects of endometriosis: an update. Am J Reprod Immunol 2011, 66(Suppl 1):101-104.
27. Augoulea A., Alexandrou A., Creatsa M., Vrachnis N., Lambrinoudaki I. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Arch Gynecol Obstet 2012, 286:99-103.
28. Christodoulakos G., Augoulea A., Lambrinoudaki I., Sioulas V., Creatsas G. Pathogenesis of endometriosis: the role of defective "immunosurveillance.". Eur J Contracept Reprod Health Care 2007, 12:194-202.
29. Oral E., Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 1997, 24:219-233.
30. Matarese G., De Placido G., Nikas Y., Alviggi C. Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune diseaseα. Trends Mol Med 2003, 9:223-228.
31. Podgaec S., Dias Junior J.A., Chapron C., Oliveira R.M., Baracat E.C., Abrão M.S. Th1 and Th2 immune responses related to pelvic endometriosis. Rev Assoc Med Bras 2010, 56:92-98.
32. Peng D.J., Liu R., Zou W. Regulatory T cells in human ovarian cancer. JOncol 2012, 2012:345164.
33. Hori S., Takahashi T., Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003, 81:331-371.
34. Berbic M., Hey-Cunningham A.J., Ng C., et al. The role of Foxp3 regulatory T-cells in endometriosis: a potential controlling mechanism for a complex, chronic immunological condition. Hum Reprod 2010, 25:900-907.
35. Podgaec S., Rizzo L.V., Fernandes L.F., Baracat E.C., Abrao M.S. CD4(+) CD25(high) Foxp3(+) cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol 2012, 68:301-308.
36. + regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Hum Reprod 2013, 28:119-124.
37. Keichel S., Barcena de Arellano M.L., Reichelt U., et al. Lymphangiogenesis in deep infiltrating endometriosis. Hum Reprod 2011, 26:2713-2720.
38. Machado D.E., Abrao M.S., Berardo P.T., Takiya C.M., Nasciutti L.E. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008, 90:148-155.
39. Pupo-Nogueira A., de Oliveira R.M., Petta C.A., Podgaec S., Dias J.A., Abrao M.S. Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis. Int J Gynaecol Obstet 2007, 99:33-37.
40. Machado D.E., Berardo P.T., Landgraf R.G., et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril 2010, 93:2674-2679.
41. Woo E.Y., Chu C.S., Goletz T.J., et al. Regulatory CD4 (1) CD25(1) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
42. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
43. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
44. Wolf D., Wolf A.M., Rumpold H., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005, 11:8326-8331.
45. Nilbert M., Pejovic T., Mandahl N., Iosif S., Willen H., Mitelman F. Monoclonal origin of endometriotic cysts. Int J Gynecol Cancer 1995, 5:61-63.
46. Jiang X., Hitchcock A., Bryan E.J., et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996, 56:3534-3539.
47. Jimbo H., Hitomi Y., Yoshikawa H., et al. Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol 1997, 150:1173-1178.
48. Jimbo H., Hitomi Y., Yoshikawa H., et al. Clonality analysis of bilateral ovarian endometrial cysts. Fertil Steril 1999, 72:1142-1143.
49. Nabeshima H., Murakami T., Yoshinaga K., Sato K., Terada Y., Okamura K. Analysis of the clonality of ectopic glands in peritoneal endometriosis using laser microdissection. Fertil Steril 2003, 80:1144-1150.
50. Tamura M., Fukaya T., Murakami T., Uehara S., Yajima A. Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalin-fixed, paraffin-embedded tissue. Lab Invest 1998, 78:213-218.
51. Wu Y., Basir Z., Kajdacsy-Balla A., et al. Resolution of clonal origins for endometriotic lesions using laser capture microdissection and the human androgen receptor (HUMARA) assay. Fertil Steril 2003, 79(Suppl 1):710-717.
52. Ali-Fehmi R., Khalifeh I., Bandyopadhyay S., et al. Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis. Int J Gynecol Pathol 2006, 25:223-229.
53. Xu B., Hamada S., Kusuki I., Itoh R., Kitawaki J. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis. Gynecol Oncol 2011, 120:239-246.
54. Kokcu A. Relationship between endometriosis and cancer from current perspective. Arch Gynecol Obstet 2011, 284:1473-1479.
55. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
56. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
57. Castiblanco G.A., Pires N.Y., Wistuba O.I., Riquelme S.E., Andrade M.L., Corvalán R.A. Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis [in Spanish]. Rev Med Chil 2006, 134:271-278.
58. Orezzoli J.P., Russell A.H., Oliva E., Del Carmen M.G., Eichhorn J., Fuller A.F. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 2008, 110:336-344.
59. Gounaris I., Charnock-Jones D.S., Brenton J.D. Ovarian clear cell carcinoma: bad endometriosis or bad endometrium. J Pathol 2011, 225:157-160.
60. Levine A.J., Perry M.E., Chang A., et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994, 69:409-416.
61. Nezhat F., Cohen C., Rahaman J., Gretz H., Cole P., Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002, 94:2935-2940.
62. Sáinz de la Cuesta R., Izquierdo M., Cañamero M., Granizo J.J. Manzarbeitia F.Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 2004, 113:87-93.
63. Akahane T., Sekizawa A., Purwosunu Y., Nagatsuka M., Okai T. The role of p53 mutation in the carcinomas arising from endometriosis. Int J Gynecol Pathol 2007, 26:345-351.
64. Gallegos-Arreola M.P., Valencia-Rodríguez L.E., Puebla-Pérez A.M., Figuera L.E., Zúñiga-González G.M. The TP53 16-bp duplication polymorphism is enriched in endometriosis patients. Gynecol Obstet Invest 2012, 73:118-123.
65. Ribeiro Júnior C.L., Arruda J.T., Silva C.T., Moura K.K. Analysis of p53 codon 72 gene polymorphism in Brazilian patients with endometriosis. Genet Mol Res 2009, 8:494-499.
66. Bianco B., Christofolini D.M., Brandes A., et al. Analysis of codon 72 polymorphism of the TP53 gene in infertile women with and without endometriosis. Rev Bras Ginecol Obstet 2011, 33:37-42.
67. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70.
68. Auner V., Kriegshauser G., Tong D., et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009, 9:111.
69. Mayr D., Hirschmann A., Lohrs U., et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006, 103:883-887.
70. Geyer J.T., Lopez-Garcia M.A., Sanchez-Estevez C., et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009, 33:1157-1163.
71. Stewart C.J., Leung Y., Walsh M.D., Walters R.J., Young J.P., Buchanan D.D. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 2012, 43:1177-1183.
72. Ratner E., Lu L., Boeke M., et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010, 70:6509-6515.
73. Kandoth C., Schultz N., Cherniack A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
74. Wiegand K.C., Shah S.P., Al-Agha O.M., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
75. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011, 11:481-492.
76. Jones S., Wang T.L., Shih Ie M., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
77. Samartzis E.P., Samartzis N., Noske A., et al. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformationα. Mod Pathol 2012, 25:885-892.
78. Xiao W., Awadallah A., Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012, 5:642-650.
79. Tsuchiya A., Sakamoto M., Yasuda J., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
80. Kato N., Sasou S., Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006, 19:83-89.
81. Kobayashi H., Kajiwara H., Kanayama S., et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary [Review]. Oncol Rep 2009, 22:233-240.
82. Kajihara H., Yamada Y., Shigetomi H., Higashiura Y., Kobayashi H. The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol 2012, 31:304-312.
83. Nyiaraneza C., Marbaix E., Smets M., Galant C., Sempoux C., Dahan K. High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome. Fam Cancer 2010, 9:383-387.
84. Martini M., Ciccarone M., Garganese G., et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002, 102:398-406.
85. Lopez J., Percharde M., Coley H.M., Webb A., Crook T. The context and potential of epigenetics in oncology. Br J Cancer 2009, 100:571-577.
86. Van Jaarsveld M.T., Helleman J., Berns E.M., Wiemer E.A. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010, 42:1282-1290.
87. Iorio M.V., Visone R., Di Leva G., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
88. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-59.
89. Dahiya N., Sherman-Baust C.A., Wang T.L., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3:e2436.
90. Zhang L., Volinia S., Bonome T., et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008, 105:7004-7009.
91. Ohlsson-Teague E.M., Van der Hoek K.H., Van der Hoek M.B., et al. MicroRNA regulated pathways associated with endometriosis. Mol. Endocrinol 2009, 23:265-275.
92. Filigheddu N., Gregnanin I., Porporato P.E., et al. Differential expression of microRNAs between eutopic and ectopic endometrium in ovarian endometriosis. J Biomed Biotechnol 2010, 2010:369549.
93. Ramón L.A., Braza-Boïls A., Gilabert-Estellés J., et al. microRNAs expression in endometriosis and their relation to angiogenic factors. Hum Reprod 2011, 26:1082-1090.
94. Gilabert-Estelles J., Braza-Boils A., Ramon L.A., et al. Role of microRNAs in gynecological pathology. Curr Med Chem 2012, 19:2406-2413.
95. Martins V.R., Dias M.S., Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 2013, 25:66-75.
96. Suryawanshi S., Vlad A.M., Lin H.M., et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013, 19:1213-1224.
97. Badgwell D., Bast R.C. Early detection of ovarian cancer. Dis Markers 2007, 23:397-410.
98. Clarke-Pearson D.L. Clinical Practice. Screening for ovarian cancer. NEngl J Med 2009, 361:170-177.
99. PROLOG Gynecology and Surgery 2009, American College of Obstetricians and Gynecologists, American College of Obstetricians and Gynecologists, Washington, DC. 6th ed.
100. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
101. Wu L., Dai Z.Y., Qian Y.H., Shi Y., Liu F.J., Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer 2012, 22:1106-1112.
102. Yu S., Yang H.J., Xie S.Q., Bao Y.X. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med 2012, 50:1439-1446.
103. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
104. Anderson K.S., Wong J., Vitonis A., et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:859-868.
105. Li F., Tie R., Chang K., et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 2012, 12:258.
106. Kim P.S., Djazayeri S., Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer [Review]. Gynecol Oncol 2011, 120:393-403.
107. Fung E.T. A recipe for proteomics diagnostic tests development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010, 56:327-329.